InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) was the target of a large decrease in short interest in June. As of June 30th, there was short interest totalling 19,000 shares, a decrease of 63.2% from the June 15th total of 51,600 shares. Based on an average daily trading volume, of 121,400 shares, the short-interest […]
InMed Pharmaceuticals (OTCMKTS:IMLFF – Free Report) is one of 374 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare InMed Pharmaceuticals to related companies based on the strength of its analyst recommendations, institutional ownership, risk, profitability, earnings, dividends and valuation. Profitability This table compares InMed Pharmaceuticals and […]
InMed Pharmaceuticals (OTCMKTS:IMLFF – Free Report) is one of 377 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare InMed Pharmaceuticals to similar companies based on the strength of its valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability. Earnings & Valuation This table compares InMed […]
InMed Pharmaceuticals (OTCMKTS:IMLFF – Free Report) is one of 365 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare InMed Pharmaceuticals to related businesses based on the strength of its dividends, institutional ownership, valuation, profitability, risk, earnings and analyst recommendations. Insider & Institutional Ownership 23.2% of shares […]
InMed Pharmaceuticals (OTCMKTS:IMLFF – Free Report) is one of 361 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare InMed Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, earnings, profitability and valuation. Earnings and Valuation This table compares InMed […]